G Niu et al. confirmed that STAT3 was directly related to VEGF induction in tumors, which suggested that targeting STAT3 for therapeutic intervention in cancer might disrupt angiogenesis induced by multiple tyrosine kinase [16], and STAT3 was an important transcription factors activating VEGF by binding to its promoter [16, 17]. This evidence concerns the gene STAT3 and cancer.